Lupin announced that it has acquired exclusive global rights to soft mist inhalation technology developed by Cambridge, UK design company TTP, and the two companies will co-develop the SMI device for delivery of inhaled drugs. Formulation development, regulatory submissions, commercial manufacturing, and commercialization of soft mist inhalers based on the TTP technology will be handled by Lupin.
TTP Managing Director Sam Hyde said, “We are excited to be partnering with Lupin to commercialize our SMI technology so that it can benefit patients suffering with chronic respiratory conditions. TTP has deep expertise in aerosol science, and we have been working with our clients for over 30 years in complex drug delivery device development; this partnership represents an exciting next step for us in this innovative area of respiratory drug delivery.”
Lupin Global CEO Vinita Gupta commented, “Inhalation is a strategic pillar of Lupin’s growth story, as we strive to bring affordable medicines to patients across the globe. The partnership with TTP for SMI technology platform is a strategic addition to our broad Inhalation capabilities.”
Lupin CEO of US Generics and Global R&D Head Alok Sonig said, “Lupin is excited to be partnering with TTP. The organizations will work together to develop products using TTP’s SMI technology that complement Lupin’s portfolio of complex inhalation products.”
Read the Lupin press release.
